The market review for March 2

Monday, March 1, the U.S. stock market was dominated by buyers due to good macroeconomic statistics and, increasingly, corporate news. From the published positive data it is worth noting than expected growth in personal expenditure and the Americans in January were higher than the January forecast of spending on construction. Both figures indicate that consumption in the United States is rising faster than expected, but it is necessary for sustained economic recovery. In addition, market participants expect the European Union declaration on measures to address the debt problems of Greece. Against this backdrop, the U.S. stock indexes spent the day in positive territory.

As a result of trading on March 1 2010. Dow Jones index rose by 78.53 points (0.76%) – to 10,403.79 points, NASDAQ rose 35.31 points (1.58%) – to 2,273.57 points, S & P added 11.22 points (1.02%) and finished the day at around 1,115.71 points.
read more

nyse    Market    

Sheller, P.C. Law Firm Instrumental in Pfizer’s $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History

PHILADELPHIA, Sept 02, 2009 /PRNewswire-USNewswire via COMTEX/ — Includes Allegations of Illicitly Promoting Antibiotic As Clinically Superior When Its Own FDA-Approved Label Said Otherwise; First-Ever Qui Tam Whistleblower Settlement of Its Type

Pfizer Inc. ignored a 2005 FDA Warning Letter to stop promoting its antibiotic Zyvox(R) as clinically superior to the significantly less expensive, generic vancomycin when its own FDA-approved label indicated otherwise. The drug giant also defrauded federal and state taxpayers by marketing Zyvox off-label, according to a qui tam whistleblower complaint filed by Philadelphia law firm Sheller, P.C. and other documents unsealed with today’s $2.3 billion Pfizer settlement.

The $2.3 billion settlement included off-label marketing allegations for the withdrawn arthritis drug Bextra(R), which was included in the Sheller complaint. Zyvox (linezolid) is an antibacterial agent that is approved by the FDA to treat certain types of infections, including nosocomial pneumonia and complicated skin and skin structure infections (”CSSSIs”) due to Methicillin Resistant Staphylococcus Aureus (”MRSA”). Worldwide sales of Zyvox totaled $1.115 billion in 2008. read more

nyse    Market